11 assets in Adenoid Cystic Carcinoma

Therapeutic assets addressing Adenoid Cystic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Adenoid Cystic Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Adenoid Cystic Carcinoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Vipivotide Tetraxetan Adenoid Cystic Carcinoma	Maria Sklodowska-Curie National Research Institute of Oncology	P2	CCC (53)
Pembrolizumab Adenoid Cystic Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1/2	CCC (52)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Adenoid Cystic Carcinoma	VM Oncology, LLC	P1/2	CC (47)
Docetaxel Adenoid Cystic Carcinoma	National Cancer Institute (NCI)	P1/2	CC (47)
Gotistobart Adenoid Cystic Carcinoma	OncoC4, Inc.	P1/2	CC (47)
SX682 Adenoid Cystic Carcinoma	National Cancer Institute (NCI)	P1/2	CC (47)
Felmetatug Vedotin Adenoid Cystic Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
nn3201 Adenoid Cystic Carcinoma	Novelty Nobility, Inc.	P1	CC (43)
Rgt-61159 Adenoid Cystic Carcinoma	Rgenta Therapeutics Inc	P1	CC (43)